Physician profile
Leah Broadhurst
NPI 1437687993
$1,017.50
in general payments reported to CMS, 2019-2025
23 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.72 · 2021: $167 · 2022: $342 · 2023: $134 · 2024: $169 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $497.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $244.02 | 2021-2024 | |
| Glaxosmithkline, LLC. | $122.25 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Novo Nordisk INC | $104.75 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $50.78 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $46.21 | 2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $45.69 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $42.88 | 2021 | |
| Gilead Sciences, INC. | $38.15 | 2022 | |
| Edwards Lifesciences Corporation | $31.64 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.41 | 2021-2022 | |
| Exact Sciences Corporation | $30.06 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.49 | 2023-2024 | Xifaxan |
| Boston Scientific Corporation | $27.40 | 2024 | Wavewriter Alpha Prime 16 |
| Sanofi-Aventis U.S. LLC | $25.58 | 2025 | |
| Abbott Laboratories | $25.14 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $20.52 | 2025 | Doc Band |
| Otsuka America Pharmaceutical, INC. | $18.00 | 2021 | |
| Shield Therapeutics INC | $16.22 | 2023 | Accrufer |
| Astellas Pharma US INC | $16.19 | 2023 | Veozah |
| Biohaven Pharmaceuticals, INC. | $14.10 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.93 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $13.29 | 2023 | Contrave |
| Novartis Pharmaceuticals Corporation | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Broadhurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.